Revenue Performance Reflects Challenging Automotive Environment
Achieved Highest Gross Margin Rate in 5 Quarters
Reduced Operating Expenses by 14%
Updates 2019 Revenue and Gross Margin Guidance
NORTHVILLE, Mich., July 25, 2019 (GLOBE NEWSWIRE) -- Gentherm (THRM), the global market leader of innovative thermal management technologies, today announced its financial results for the second quarter ended June 30, 2019.
Second Quarter Highlights
- Product revenues of $243.3 million decreased 8.7% from $266.4 million in the 2018 second quarter
- Excluding the impact of foreign currency translation, divested assets and assets held for sale, product revenues decreased 1.9% year over year
- GAAP diluted earnings per share was $0.08 as compared to $0.45 for the prior-year period
- Adjusted earnings per share (see table herein) was $0.47. Adjusted earnings per share in the prior-year period was $0.58
- Secured automotive new business awards totaling $260 million
- Repurchased $25 million of the Company’s stock
Phil Eyler, the Company's President and CEO, said “We continued to make progress with our focused growth strategy, achieved our highest gross margin rate in five quarters and reduced operating expenses by 14 percent from a year ago. Our Medical business grew double digits in the quarter as we successfully added Stihler products to our portfolio.”
“In Automotive, we secured over $2.2 billion of new awards from top auto makers around the world in the last six quarters and consistently outperformed actual light vehicle production in our key markets. However, the production environment continues to deteriorate, putting downward pressure on our revenue growth trajectory. While we are reducing our revenue guidance for 2019, we are tightening our gross margin range and maintaining our profitability guidance as we continue to improve our cost performance through the Fit-for-Growth program,” continued Eyler.
2019 Second Quarter Financial Review
Product revenues for the second quarter of 2019 of $243.3 million declined $23.1 million, or 8.7%, as compared to the prior-year period. Excluding the impact of foreign currency translation, divested assets and assets held for sale, product revenues declined 1.9% year over year.
Automotive revenues declined 5.5% year over year. All product categories saw revenue declines except Battery Thermal Management (BTM) and Other Automotive. Adjusting for foreign currency translation, organic Automotive revenues decreased 3.0% year over year. When compared with IHS Markit's mid-April forecast for the second quarter of 2019, actual light vehicle production was approximately 4 percentage points below forecast. In addition, when compared to the second quarter of 2018, actual global light vehicle production declined by 8%.
The revenue decline in the Industrial segment resulted from the absence of revenue in this year’s second quarter from the divested Cincinnati Sub-Zero (CSZ) industrial chamber business and lower sales in the Global Power Technologies (GPT) business, which has been classified as “assets held for sale.” The decline was partially offset by higher medical revenue. Gentherm Medical revenue grew 30.7% year over year as a result of the Stihler acquisition that occurred in the first quarter of 2019, as well as higher Blanketrol sales.
See the “Revenue by Product Category” table included below for additional detail.
The gross margin rate increased to 29.9% in the current-year period, a 100-basis point improvement over the prior-year period, primarily as a result of supplier cost reductions, higher labor productivity and Fit-for-Growth cost reduction initiatives. These were partially offset by annual customer price reductions, wage inflation, tariffs, as well as the negative fixed cost leverage from lower unit volume. On a sequential basis, the gross margin rate improved 70 basis points.
Net research and development (R&D) expenses of $19.3 million in the second quarter of 2019 decreased $1.8 million, or 8.5%, year over year as a direct result of the Company’s focused portfolio and Fit-for-Growth cost reduction initiatives.
Selling, general and administrative (SG&A) expenses of $31.8 million in the second quarter of 2019 decreased $2.4 million, or 7.1%, versus the prior-year period. The year-over-year decline was primarily driven by the sale of the CSZ industrial chambers business and the impact of the Fit-for-Growth cost reduction initiatives.
During the quarter, the Company recognized $1.2 million in restructuring expenses which resulted from completed actions associated with its Fit-for-Growth initiatives. Total implemented actions to date are expected to deliver annualized savings of approximately $42 million. The Company has identified a total of $68 million of savings against its annualized target of $75 million by 2021.
As described more fully in the table included below, “Reconciliation of Net Income to Adjusted EBITDA,” the Company recorded Adjusted EBITDA of $32.2 million during the second quarter of 2019 compared to $35.5 million in the prior year, a year-over-year decrease of $3.3 million or 9.5%.
Income tax expense in the 2019 second quarter was $5.5 million, as compared with $3.1 million in the prior-year period. Adjusting for the $9.9 million non-deductible impairment loss, the effective tax rate for the quarter was 30.5%. This rate differed from the Federal statutory rate of 21%, primarily due to higher tax rates in foreign tax jurisdictions.
GAAP diluted earnings per share for the second quarter of 2019 was $0.08 compared with $0.45 for the prior-year period. Adjusted diluted earnings per share, excluding restructuring expenses, impairment charges, unrealized currency gain, and other impacts (see table herein), was $0.47. Adjusted diluted earnings per share in the prior-year period was $0.58.
Based on the Company’s second quarter results and the challenging macroeconomic environment, Gentherm is updating its revenue and gross margin guidance, while maintaining all other guidance metrics, for 2019 excluding the impact of foreign currency translation, divested assets and assets held for sale as follows:
- Product revenues are expected to grow between 0% and 2%
- Operating expenses between 19% and 20% of product revenues
- Gross margin rate between 29% and 30%
- Adjusted EBITDA between 14% and 15% of product revenue
- Full-year effective tax rate between 28% and 30%
- Capital expenditures between $40 and $50 million
As previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-877-407-4018 (callers in the U.S.) or +1-201-689-8471 (callers outside this U.S.). The passcode for the live call is 13692030.
A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.
A telephonic replay will be available approximately 2 hours after the call until 11:59 pm Eastern Time on August 8, 2019. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 13692030.
Investor Relations Contact
Gentherm (THRM) is a global developer and marketer of innovative thermal management technologies for a broad range of heating and cooling and temperature control applications. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery thermal management systems, cable systems and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has over 13,000 employees in facilities in the United States, Germany, Canada, China, Hungary, Japan, Korea, North Macedonia, Malta, Mexico, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.
Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this release are made as of the date hereof or as of the date specified and are based on management's current expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause the Company's actual performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that new products may not be feasible, sales may not increase, new competitors may arise or customers may develop their own products to replace the Company’s products, customer preferences for end products may shift, the Company may lose suppliers or customers, market acceptance of the Company’s existing or new products may decrease, currency exchange rates may change unfavorably, pricing pressures from customers may increase, current and projected future declines in automobile production may have an adverse impact, the macroeconomic environment may present adverse conditions, additional financing requirements may not be available, the Company’s workforce and operations could be disrupted by civil or political unrest in the countries in which the Company operates, free trade agreements may be altered in a manner adverse to the Company, our customers may not accept pass-through of new tariff costs, additional tariffs may be implemented, cost-savings measures may not be achievable or may need to be reversed, assets held for sale may not be sold quickly or at all, the Company may be unable to repurchase its shares of common stock at favorable prices or at all, due to market conditions, applicable legal requirements, debt covenants or other restrictions, compliance with covenants and other restrictions under the Company’s credit facility, medical device regulations could change in an unfavorable manner, oil and gas prices could fluctuate causing adverse consequences, and other adverse conditions in the industries in which the Company operates may negatively affect its results.
The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent quarterly reports, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this release does not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof.
Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(In thousands, except per share data)
|Three Months Ended |
|Six Months Ended |
|Cost of sales||170,612||189,308||353,226||372,652|
|Net research and development expenses||19,255||21,022||38,152||44,326|
|Selling, general and administrative expenses||31,829||34,262||64,442||70,686|
|Acquisition transaction expense||342||—||380||—|
|Total operating expenses||52,657||61,499||106,119||122,092|
|Foreign currency (loss) gain||(804||)||5,174||(601||)||596|
|Gain on sale of business||—||—||4,970||—|
|Earnings before income tax||8,299||19,742||23,608||35,744|
|Income tax expense||5,548||3,083||12,443||6,119|
|Basic earnings per share||$||0.08||$||0.46||$||0.33||$||0.81|
|Diluted earnings per share||$||0.08||$||0.45||$||0.33||$||0.81|
|Weighted average number of shares – basic||33,441||36,523||33,508||36,560|
|Weighted average number of shares – diluted||33,574||36,667||33,651||36,663|
|REVENUE BY PRODUCT CATEGORY|
|(Unaudited, in thousands)|
|Three Months Ended |
|Six Months Ended |
|2019||2018(1)||% Diff.||2019||2018(1)||% Diff.|
|Climate Controlled Seat (CCS)||$||88,437||$||90,395||(2.1||)%||$||182,791||$||178,613||2.3||%|
|Steering Wheel Heaters||16,029||17,540||(8.6||)%||32,999||35,097||(6.0||)%|
|Battery Thermal Management (BTM)||8,897||7,241||22.9||%||19,641||11,402||72.3||%|
|Remote Power Generation (GPT)||3,745||5,270||(28.9||)%||7,704||9,932||(22.4||)%|
|Total Core Businesses (Automotive and Gentherm Medical)||$||239,581||$||250,712||(4.4||)%||$||490,125||$||500,423||(2.1||)%|
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
|Three Months Ended |
|Six Months Ended |
|Income tax expense||5,548||3,083||12,443||6,119|
|Depreciation and amortization||11,094||12,859||22,074||25,679|
|Impairment of assets held for sale||9,885||—||20,369||—|
|Gain on sale of business||—||—||(4,970||)||—|
|Acquisition transaction expenses||342||—||380||—|
|Unrealized currency loss (gain)||71||(4,532||)||(923||)||(890||)|
|CFO transition expense||—||—||1,065||—|
Use of Non-GAAP Financial Measures
In addition to the results reported in accordance with GAAP throughout this release, the Company has provided information regarding adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”) and adjusted earnings per share (“Adjusted earnings per share” or “Adjusted EPS”), each, a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Adjusted EPS as earnings adjusted by gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company’s reconciliation of net income to Adjusted EBITDA is provided in this release. The Company’s Reconciliation of Adjusted EPS can be found in the supplemental materials furnished as Exhibit 99.2 to the Company’s Form 8-K dated July 25, 2019 and also is included in the presentation entitled “Q2 2019 Gentherm Incorporated Earnings Conference Call Release,” which can be found on the Events page of the Investor section of Gentherm's website at www.gentherm.com.
In evaluating its business, the Company considers and uses Adjusted EBITDA and Adjusted EPS as supplemental measures of its operating performance. Management provides Adjusted EBITDA and Adjusted EPS measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis. Other companies in our industry may calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA or Adjusted EPS in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP.
Non-GAAP measures referenced in this release may include estimates of future Adjusted EBITDA and Adjusted EPS. Such forward-looking non-GAAP measures may differ significantly from the corresponding GAAP measures, due to depreciation and amortization, tax expense, and/or interest expense, some or all of which management has not quantified for the future periods.
ACQUISITION TRANSACTION EXPENSES, PURCHASE ACCOUNTING IMPACTS
AND OTHER EFFECTS
(In thousands, except per share data)
|Three Months Ended||Six Months Ended|
|June 30,||June 30,||Future Full Year Periods (estimated)|
|Transaction related current expenses|
|Acquisition transaction expenses||$||342||$||—||$||380||$||—||$ 380||$||—||$||—||$||—||$||—|
|Non-cash purchase accounting impacts|
|Customer relationships amortization||1,936||2,607||3,764||5,273||7,677||6,569||6,003||5,581||20,905|
|Inventory fair value adjustment||117||30||156||59||462||447||—||—||—|
|Gain on sale of business||—||—||(4,970||)||—||(4,970)||—||—||—||—|
|Unrealized currency loss (gain)||71||(4,532)||(923||)||(890||)||(923)||—||—||—||—|
|Total acquisition transaction expenses, purchase accounting impacts and other effects||$||14,080||$||5,366||$||23,966||$||13,374||$||29,191||$||9,028||$||8,007||$||7,526||$||25,968|
|Tax effect of above||(1,117||)||(711)||(905||)||(2,452||)||(2,236)||(2,313||)||(2,037||)||(1,914||)||(6,571)|
|Net income effect||$||12,963||$||4,655||$||23,061||$||10,922||$26,955||$||6,715||5,970||5,612||$||19,397|
|Earnings per share - difference|
|Adjusted earnings per share|
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
|June 30, |
|December 31, |
|Cash and cash equivalents||$||33,677||$||39,620|
|Accounts receivable, less allowance of $1,399 and $851, respectively||171,640||166,858|
|Work in process||6,660||5,939|
|Derivative financial instruments||1,155||92|
|Prepaid expenses and other assets||50,128||54,271|
|Assets held for sale||6,714||69,699|
|Total current assets||378,431||443,075|
|Property and equipment, net||169,345||171,380|
|Other intangible assets, net||55,479||56,385|
|Operating lease right-of-use assets||13,267||—|
|Deferred financing costs||1,782||647|
|Deferred income tax assets||60,071||64,024|
|Other non-current assets||8,421||12,225|
|LIABILITIES AND SHAREHOLDERS’ EQUITY|
|Current lease liabilities||5,031||—|
|Current maturities of long-term debt||2,955||3,413|
|Liabilities held for sale||6,714||13,062|
|Total current liabilities||161,415||175,396|
|Pension benefit obligation||6,765||7,211|
|Non-current lease liabilities||7,741||—|
|Long-term debt, less current maturities||104,393||136,477|
|Deferred income tax liabilities||2,577||1,177|
|Other non-current liabilities||3,738||3,087|
|No par value; 55,000,000 shares authorized, 33,147,567 and 33,856,629 issued and outstanding at June 30, 2019 and December 31, 2018, respectively|| |
|Accumulated other comprehensive loss||(39,440||)||(39,500||)|
|Total shareholders’ equity||465,281||479,699|
|Total liabilities and shareholders’ equity||$||751,910||$||803,047|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|Six Months Ended June 30,|
|Adjustments to reconcile net income to cash provided by operating activities:|
|Depreciation and amortization||22,217||25,823|
|Deferred income taxes||3,070||(1,799||)|
|Defined benefit plan income||(699||)||(103||)|
|Provision of doubtful accounts||545||204|
|Loss on sale of property and equipment||227||2,156|
|Operating lease expense||2,903||—|
|Gain on sale of business||(4,970||)||—|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||276||(12,094||)|
|Net cash provided by operating activities||40,408||32,543|
|Proceeds from the sale of property and equipment||82||698|
|Proceeds from sale of a business||47,500||—|
|Acquisition of subsidiary, net of cash acquired||(15,476||)||(15||)|
|Purchases of property and equipment||(13,024||)||(22,138||)|
|Net cash provided by (used in) investing activities||19,082||(21,455||)|
|Borrowing of debt||28,371||15,000|
|Repayments of debt||(61,120||)||(46,742||)|
|Cash paid for financing costs||(1,278||)||—|
|Cash paid for the cancellation of restricted stock||(926||)||(882||)|
|Proceeds from the exercise of Common Stock options||4,771||4,966|
|Repurchase of Common Stock||(33,040||)||(20,241||)|
|Net cash used in financing activities||(63,222||)||(47,899||)|
|Foreign currency effect||293||(1,004||)|
|Net decrease in cash, cash equivalents and restricted cash||(3,439||)||(37,815||)|
|Cash, cash equivalents and restricted cash at beginning of period||39,620||103,172|
|Cash, cash equivalents and restricted cash at end of period||$||36,181||$||65,357|
|Supplemental disclosure of cash flow information:|
|Cash paid for taxes||$||3,522||$||18,100|
|Cash paid for interest||$||2,712||$||2,608|
|Supplemental disclosure of non-cash transactions:|
|Common Stock issued to Board of Directors and employees||$||3,605||$||2,419|